Latest Pharma Insights
Lilly Engages Haisco In Five-Drug Collaboration
Deal Snapshot: In its second deal with an Asian company in two days, Lilly agreed to pay Haisco up to $3.05bn in upfront, near-term and milestone fees to discover up to five new drug candidates.
Scrip - June 1, 2026
Deal Snapshot: In its second deal with an Asian company in two days, Lilly agreed to pay Haisco up to $3.05bn in upfront, near-term and milestone fees to discover up to five new drug candidates.
Scrip - June 1, 2026
Child Death Overseas Prompts KayserBetten To Replace Hand Controls On Pediatric Care Beds In US
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
Wockhardt’s Novel Drug Zaynich To Hit US In 2026, EU Likely Next Year
Wockhardt’s antibiotic Zaynich, India’s first novel drug to be developed and successfully taken to US approval by the same company, will launch in the US in 2026 with a new commercial team and is also likely to hit shelves in Europe next year, says chairman Habil Khorakiwala.
Scrip - June 1, 2026
Wockhardt’s antibiotic Zaynich, India’s first novel drug to be developed and successfully taken to US approval by the same company, will launch in the US in 2026 with a new commercial team and is also likely to hit shelves in Europe next year, says chairman Habil Khorakiwala.
Scrip - June 1, 2026
Global Medtech Guidance Tracker: May 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
Cooper Acquires Spain’s ‘Number-One Analgesic’ As Ferrer Exits OTC
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
Samsung Bioepis Joins EU Eylea Rivals
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
A Technology Problem Disguised As A Trust Problem: J&J’s Polyphonic Chief On Scaling Surgical AI
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
ASCO: Lilly Details Game-Changing Retevmo Data In Lung Cancer
The latest results on the RET inhibitor could establish a new standard of care for a rare subset of NSCLC.
Scrip - June 1, 2026
The latest results on the RET inhibitor could establish a new standard of care for a rare subset of NSCLC.
Scrip - June 1, 2026
ASCO: BioNTech, Bristol Myers Squibb Advance Pumitamig To Phase III After NSCLC Data Readout
Encouraging efficacy signals and a manageable safety profile have prompted BioNTech and Bristol Myers Squibb to push pumitamig deeper into late-stage development.
Scrip - June 1, 2026
Encouraging efficacy signals and a manageable safety profile have prompted BioNTech and Bristol Myers Squibb to push pumitamig deeper into late-stage development.
Scrip - June 1, 2026
The ‘Unglamorous’ Bet: MedRenova’s AI-Driven Case For Drug Repurposing
MedRenova's repurposing engine runs on AI/ML, surfacing "unconventional" drug combos, co-crystals etc, says CEO Dhananjay Bakhle. An ulcerative colitis therapy is in its sights, while areas of unmet need such as suicidal tendencies and alopecia areata are of interest.
Scrip - June 1, 2026
MedRenova's repurposing engine runs on AI/ML, surfacing "unconventional" drug combos, co-crystals etc, says CEO Dhananjay Bakhle. An ulcerative colitis therapy is in its sights, while areas of unmet need such as suicidal tendencies and alopecia areata are of interest.
Scrip - June 1, 2026
Ten-Year Data Show Edwards’ RESILIA Tissue Valves Hold Up Even In Younger Patients
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Teva’s TAPI Sale Hits Succession Question
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
Pipeline Watch: Ten Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 1, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 1, 2026
ASCO: Gilead Presents Early Data For GBM CAR-T
The company presented Phase I data showing some patients had extended survival in recurrent GBM. An executive also talked to Scrip about Gilead’s commercialization of anito-cel.
Scrip - June 1, 2026
The company presented Phase I data showing some patients had extended survival in recurrent GBM. An executive also talked to Scrip about Gilead’s commercialization of anito-cel.
Scrip - June 1, 2026
China Approval Seals Henlius’ Global Breast Cancer Play
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
Is European ‘Reliability’ Enough In The Moving Picture Of Global Markets?
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
EU Medtech CEOs Keen To Map Out The Fixes From Draghi Report
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
What’s Next? Five Things To Look Out For In June
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
The Nighttime Evidence Gap: How Passive Monitoring Could Reshape Trial Endpoints
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026
Lilly Bolsters Gastrointestinal Portfolio Via $1.26bn Hanmi Deal
Lilly secures global rights to Hanmi’s long-acting GLP-2 analog sonefpeglutide for short bowel syndrome and other indications, in a deal worth up to $1.26bn plus royalties.
Scrip - June 1, 2026
Lilly secures global rights to Hanmi’s long-acting GLP-2 analog sonefpeglutide for short bowel syndrome and other indications, in a deal worth up to $1.26bn plus royalties.
Scrip - June 1, 2026
ASCO: Ivonescimab’s First OS Win Over PD-1 In Lung Cancer Suggests Strengths Vs Keytruda
Akeso’s ivonescimab has snagged the first OS win for a PD-(L)1 x VEGF bispecific over PD-(L)1 inhibitors in a China-only head-to-head trial in first-line squamous non-small cell lung cancer. The drug’s strengths against Keytruda are also taking shape in the two-year OS rate.
Scrip - June 1, 2026
Akeso’s ivonescimab has snagged the first OS win for a PD-(L)1 x VEGF bispecific over PD-(L)1 inhibitors in a China-only head-to-head trial in first-line squamous non-small cell lung cancer. The drug’s strengths against Keytruda are also taking shape in the two-year OS rate.
Scrip - June 1, 2026
What Korea Needs To Do To Become A Truly Global Player
A Bio Korea session heard experts say the country must develop stronger commercialization expertise, share the financial burden of late-stage trials, and foster closer government and industry collaboration if it is to produce global blockbuster new drugs.
Scrip - June 1, 2026
A Bio Korea session heard experts say the country must develop stronger commercialization expertise, share the financial burden of late-stage trials, and foster closer government and industry collaboration if it is to produce global blockbuster new drugs.
Scrip - June 1, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s new data protections.
Scrip - June 1, 2026
In this week's episode: can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s new data protections.
Scrip - June 1, 2026
Lilly Engages Haisco In Five-Drug Collaboration
Deal Snapshot: In its second deal with an Asian company in two days, Lilly agreed to pay Haisco up to $3.05bn in upfront, near-term and milestone fees to discover up to five new drug candidates.
Scrip - June 1, 2026
Deal Snapshot: In its second deal with an Asian company in two days, Lilly agreed to pay Haisco up to $3.05bn in upfront, near-term and milestone fees to discover up to five new drug candidates.
Scrip - June 1, 2026
Wockhardt’s Novel Drug Zaynich To Hit US In 2026, EU Likely Next Year
Wockhardt’s antibiotic Zaynich, India’s first novel drug to be developed and successfully taken to US approval by the same company, will launch in the US in 2026 with a new commercial team and is also likely to hit shelves in Europe next year, says chairman Habil Khorakiwala.
Scrip - June 1, 2026
Wockhardt’s antibiotic Zaynich, India’s first novel drug to be developed and successfully taken to US approval by the same company, will launch in the US in 2026 with a new commercial team and is also likely to hit shelves in Europe next year, says chairman Habil Khorakiwala.
Scrip - June 1, 2026
ASCO: Lilly Details Game-Changing Retevmo Data In Lung Cancer
The latest results on the RET inhibitor could establish a new standard of care for a rare subset of NSCLC.
Scrip - June 1, 2026
The latest results on the RET inhibitor could establish a new standard of care for a rare subset of NSCLC.
Scrip - June 1, 2026
ASCO: BioNTech, Bristol Myers Squibb Advance Pumitamig To Phase III After NSCLC Data Readout
Encouraging efficacy signals and a manageable safety profile have prompted BioNTech and Bristol Myers Squibb to push pumitamig deeper into late-stage development.
Scrip - June 1, 2026
Encouraging efficacy signals and a manageable safety profile have prompted BioNTech and Bristol Myers Squibb to push pumitamig deeper into late-stage development.
Scrip - June 1, 2026
The ‘Unglamorous’ Bet: MedRenova’s AI-Driven Case For Drug Repurposing
MedRenova's repurposing engine runs on AI/ML, surfacing "unconventional" drug combos, co-crystals etc, says CEO Dhananjay Bakhle. An ulcerative colitis therapy is in its sights, while areas of unmet need such as suicidal tendencies and alopecia areata are of interest.
Scrip - June 1, 2026
MedRenova's repurposing engine runs on AI/ML, surfacing "unconventional" drug combos, co-crystals etc, says CEO Dhananjay Bakhle. An ulcerative colitis therapy is in its sights, while areas of unmet need such as suicidal tendencies and alopecia areata are of interest.
Scrip - June 1, 2026
Pipeline Watch: Ten Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 1, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 1, 2026
ASCO: Gilead Presents Early Data For GBM CAR-T
The company presented Phase I data showing some patients had extended survival in recurrent GBM. An executive also talked to Scrip about Gilead’s commercialization of anito-cel.
Scrip - June 1, 2026
The company presented Phase I data showing some patients had extended survival in recurrent GBM. An executive also talked to Scrip about Gilead’s commercialization of anito-cel.
Scrip - June 1, 2026
Lilly Bolsters Gastrointestinal Portfolio Via $1.26bn Hanmi Deal
Lilly secures global rights to Hanmi’s long-acting GLP-2 analog sonefpeglutide for short bowel syndrome and other indications, in a deal worth up to $1.26bn plus royalties.
Scrip - June 1, 2026
Lilly secures global rights to Hanmi’s long-acting GLP-2 analog sonefpeglutide for short bowel syndrome and other indications, in a deal worth up to $1.26bn plus royalties.
Scrip - June 1, 2026
ASCO: Ivonescimab’s First OS Win Over PD-1 In Lung Cancer Suggests Strengths Vs Keytruda
Akeso’s ivonescimab has snagged the first OS win for a PD-(L)1 x VEGF bispecific over PD-(L)1 inhibitors in a China-only head-to-head trial in first-line squamous non-small cell lung cancer. The drug’s strengths against Keytruda are also taking shape in the two-year OS rate.
Scrip - June 1, 2026
Akeso’s ivonescimab has snagged the first OS win for a PD-(L)1 x VEGF bispecific over PD-(L)1 inhibitors in a China-only head-to-head trial in first-line squamous non-small cell lung cancer. The drug’s strengths against Keytruda are also taking shape in the two-year OS rate.
Scrip - June 1, 2026
What Korea Needs To Do To Become A Truly Global Player
A Bio Korea session heard experts say the country must develop stronger commercialization expertise, share the financial burden of late-stage trials, and foster closer government and industry collaboration if it is to produce global blockbuster new drugs.
Scrip - June 1, 2026
A Bio Korea session heard experts say the country must develop stronger commercialization expertise, share the financial burden of late-stage trials, and foster closer government and industry collaboration if it is to produce global blockbuster new drugs.
Scrip - June 1, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s new data protections.
Scrip - June 1, 2026
In this week's episode: can GLP-1s help in cancer; Novartis on its cardiovascular strategy; Lilly’s retatrutide looks promising in obesity; Lilly’s raises cell and gene therapy bet; and the business impact of China’s new data protections.
Scrip - June 1, 2026
Child Death Overseas Prompts KayserBetten To Replace Hand Controls On Pediatric Care Beds In US
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
Global Medtech Guidance Tracker: May 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
A Technology Problem Disguised As A Trust Problem: J&J’s Polyphonic Chief On Scaling Surgical AI
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
Ten-Year Data Show Edwards’ RESILIA Tissue Valves Hold Up Even In Younger Patients
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Is European ‘Reliability’ Enough In The Moving Picture Of Global Markets?
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
Cooper Acquires Spain’s ‘Number-One Analgesic’ As Ferrer Exits OTC
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
Samsung Bioepis Joins EU Eylea Rivals
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
Teva’s TAPI Sale Hits Succession Question
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
China Approval Seals Henlius’ Global Breast Cancer Play
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
What’s Next? Five Things To Look Out For In June
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
EU Medtech CEOs Keen To Map Out The Fixes From Draghi Report
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
The Nighttime Evidence Gap: How Passive Monitoring Could Reshape Trial Endpoints
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026